| Bioactivity | PLX-3618 is a monovalent direct degrader for BRD4 with DC50 of 12.2 nM. PLX-3618 promotes polyubiquitination and subsequent proteasomal degradation of BRD4 by recruiting of the E3 ligase substrate receptor, DCAF11. PLX-3618 inhibits the proliferation of various cancer cells, induces apoptosis in AML cells. PLX-3618 exhibits antitumor activity against AML in mouse models[1]. |
| CAS | 2851986-76-8 |
| Formula | C32H27N9O2S |
| Molar Mass | 601.68 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Parker GS, et al., Discovery of Monovalent Direct Degraders of BRD4 That Act Via the Recruitment of DCAF11. Mol Cancer Ther. 2024 Jun 22. |
PLX-3618
CAS: 2851986-76-8 F: C32H27N9O2S W: 601.68
PLX-3618 is a monovalent direct degrader for BRD4 with DC50 of 12.2 nM. PLX-3618 promotes polyubiquitination and subsequ
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.